FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This survey is conducted for preparing application materials for re-examination under the
Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the
clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS D through collecting the safety
information according to the Re-examination Regulation for New Drugs.
Note: FOSAMAX PLUS D is known as FOSAMAX PLUS in several markets. FOSAMAX PLUS (70 mg/2800
IU) and FOSAMAX PLUS D (70 mg/5600 IU).